Beta Blockers After MI and Preserved EF

reduce ami trial

Year: 2024 Title: REDUCE-AMI Subtitle: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction Type of Trial: A randomized, parallel-group, open-label trial

Objective: To determine whether long-term treatment with oral beta-blockade in patients with myocardial infarction and preserved left ventricular systolic ejection fraction reduces the composite of death of any cause or new myocardial infarction.

Patients: 5020

Inclusion Criteria:

  • Age ≥18 years
  • Day 1-7 after MI
  • Undergone coronary angiography during hospitalization
  • Obstructive coronary artery disease documented by coronary angiography and EF≥50%

Exclusion Criteria: Contraindications for beta-blockade.


  • Beta-Blocker Group (n = 2508)
  • No-Beta-Blocker Group (n = 2512)

Primary Outcome:

  • A composite of death from any cause or new myocardial infarction %
  • HR, 0.96; 95% CI, 0.79 to 1.16 (P=0.64)
  • Beta-Blocker Group: 7.9%
  • No-Beta-Blocker Group: 8.3%

Secondary Outcomes:

  • Death from any cause %
    • Beta-Blocker Group: 3.9%
    • No-Beta-Blocker Group: 4.1%
  • Hospitalization for atrial fibrillation %
    • Beta-Blocker Group: 1.1%
    • No-Beta-Blocker Group: 1.4%

Conclusion: Among patients with acute myocardial infarction who underwent early coronary angiography and had a preserved left ventricular ejection fraction (≥50%), long-term beta-blocker treatment did not lead to a lower risk of the composite primary endpoint of death from any cause or new myocardial infarction than no beta-blocker use.

Reference: Yndigegn T et al. N Engl J Med 2024; DOI: 10.1056/NEJMoa2401479

Comments are closed.